Bringing the fundamentals into focus…
Back to Bright Minds Biosciences Inc.
How Bright Minds Biosciences Inc. stacks up
DRUG · against 249 other Healthcare companies of similar size
Valuation
33/ 100
Below the middle of the pack.
Ranked #122 of 250 · scores higher than 41% of peers
Bars: peers in each 10-point band of the valuation score44 peers with a valuation score of 30–39, including DRUG · Click a bar to see the companies
Why valuation scores 33?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -1.0% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -8.3% vs peer median 0.0%
- Cash exceeds market value plus debt, so EBITDA yield is not meaningful and is left out.
Metric by metric
Position: dot = DRUG, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | DRUG | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 233 reported | Not reported | -1.3% | — | — | 30% |
| EBITDA yieldHigher is better · 256 reported | Not reported | 1.4% | — | — | 50% |
| Free cash flow yieldHigher is better · 144 reported | -8.3% | -12.4% | 60% | 20% | |
| Book yieldHigher is better · 238 reported | Not reported | 61.4% | — | — | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around DRUG| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 834M HKD (≈$107M) | 99 | 57 | |
| 1 | 1.4B HKD (≈$181M) | 99 | 61 | |
| 1 | 2.9B HKD (≈$365M) | 99 | 84 | |
| 1 | 3.1B HKD (≈$396M) | 99 | 61 | |
| 122 | 186M USD | 33 | 43 | |
| 122 | 257M USD | 33 | 55 | |
| 122 | 274M USD | 33 | 57 | |
| 122 | 110M USD | 33 | 38 | |
| 122 | 213M USD | 33 | ||
| 122 | 109M USD | 33 | 47 | |
| 122 | 216M USD | 33 | 44 | |
| 122 | 126M USD | 33 | 32 | |
| 122 | 285M USD | 33 | 38 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score